Phoenix Life Sciences International Limited Overview
Industry: Drug Manufacturers—Specialty & Generic
Sector: Healthcare
Phoenix Life Sciences International Limited operates as a healthcare solutions company in the United States and internationally. The company focuses on advancing research, integrating programs, and manufacturing of products that target and treat diabetes, pain, and cancers, as well as address psychological, gastrointestinal, autoimmune, neurological, and sleep disorders. It offers oral soft gel capsules, thin film dissolvable strips, transdermal patches, sublingual oral sprays, suppositories, and topical creams. The company was formerly known as Stem Bioscience, Inc. and changed its name to Phoenix Life Sciences International Limited in May 2018. Phoenix Life Sciences International Limited was incorporated in 2009 and is headquartered in Las Vegas Nevada.
Phoenix Life Sciences International Limited is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Phoenix Life Sciences International Limited in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Phoenix Life Sciences International Limited Competitors
Phoenix Life Sciences International Limited operates in the Drug Manufacturers—Specialty & Generic industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans